Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?

Objective. To assess trends in cardiovascular (CV) mortality in patients with incident rheumatoid arthritis (RA) in 2000–07 versus the previous decades, compared with non-RA subjects. Methods. The study population consisted of Olmsted County, Minnesota, USA residents with incident RA (age ≥ 18 yrs, 1987 American College of Rheumatology criteria was met in 1980–2007) and non-RA subjects from the same underlying population with similar age, sex, and calendar year of index. All subjects were followed until death, migration, or December 31, 2014. Followup was truncated for comparability. Aalen-Johansen methods were used to estimate CV mortality rates, adjusting for competing risk of other causes. Cox proportional hazards models were used to compare CV mortality by decade. Results. The study included 813 patients with RA and 813 non-RA subjects (mean age 55.9 yrs; 68% women for both groups). Patients with incident RA in 2000–07 had markedly lower 10-year overall CV mortality (2.7%, 95% CI 0.6–4.9%) and coronary heart disease (CHD) mortality (1.1%, 95% CI 0.0–2.7%) than patients diagnosed in 1990–99 (7.1%, 95% CI 3.9–10.1% and 4.5%, 95% CI 1.9–7.1%, respectively; HR for overall CV death: 0.43, 95% CI 0.19–0.94; CHD death: HR 0.21, 95% CI 0.05–0.95). This improvement in CV mortality persisted after accounting for CV risk factors. Ten-year overall CV mortality and CHD mortality in 2000–07 RA incidence cohort was similar to non-RA subjects (p = 0.95 and p = 0.79, respectively). Conclusion. Our findings suggest significantly improved overall CV mortality, particularly CHD mortality, in patients with RA in recent years. Further studies are needed to examine the reasons for this improvement.

[1]  O. Schieir,et al.  The effect of rheumatoid arthritis–associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis , 2017, Rheumatology.

[2]  C. Formosa,et al.  Determining the presence of Peripheral Arterial Disease in patients with Rheumatoid Arthritis , 2017, Mediterranean journal of rheumatology.

[3]  M. Abrahamowicz,et al.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap , 2016, Annals of the rheumatic diseases.

[4]  J. Primdahl,et al.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update , 2016, Annals of the rheumatic diseases.

[5]  H. Boshuizen,et al.  Trend in and predictors for cardiovascular mortality in patients with rheumatoid arthritis over a period of 15 years: a prospective cohort study. , 2016, Clinical and experimental rheumatology.

[6]  W. Dixon,et al.  Oral glucocorticoid therapy and all-cause and cause-specific mortality in patients with rheumatoid arthritis: a retrospective cohort study , 2016, European Journal of Epidemiology.

[7]  Shun-Chiao Chang,et al.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow‐Up: Results From the Nurses’ Health Study , 2016, Arthritis care & research.

[8]  M. Nørgaard,et al.  Rheumatoid Arthritis: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden , 2015, The Journal of Rheumatology.

[9]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[10]  L. Virta,et al.  No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008. , 2015, Clinical and experimental rheumatology.

[11]  K. Fukao,et al.  Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. , 2014, Journal of cardiology.

[12]  T. Therneau,et al.  Time Trends in Glucocorticoid Use in Rheumatoid Arthritis: Results From a Population‐Based Inception Cohort, 1980–1994 Versus 1995–2007 , 2014, Arthritis care & research.

[13]  M. Lunt,et al.  Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register , 2014, Arthritis care & research.

[14]  L. Jacobsson,et al.  The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study , 2014, Arthritis Research & Therapy.

[15]  M. A. van de Laar,et al.  Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature , 2014, BMC Musculoskeletal Disorders.

[16]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[17]  J. Spence.  Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2013 .

[18]  W. Ghali,et al.  Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis , 2011, Arthritis care & research.

[19]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[20]  M. Hochberg,et al.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[21]  T. Therneau,et al.  Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. , 2010, Arthritis and rheumatism.

[22]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[23]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[24]  L. Trinquart,et al.  Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. , 2009, Rheumatology.

[25]  D. Symmons,et al.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[26]  Mohsen Sadatsafavi,et al.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. , 2008, Arthritis and rheumatism.

[27]  T. Therneau,et al.  The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. , 2008, Arthritis and rheumatism.

[28]  F. Wolfe,et al.  The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. , 2008, Arthritis and rheumatism.

[29]  T. Pincus,et al.  Mortality in rheumatoid arthritis: 2008 update. , 2008, Clinical and experimental rheumatology.

[30]  W. Gross,et al.  A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. , 2008, Clinical and experimental rheumatology.

[31]  I. Bruce,et al.  The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis , 2008, Arthritis and rheumatism.

[32]  T. Pincus,et al.  Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study , 2008, Arthritis research & therapy.

[33]  M. Hochberg,et al.  The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006 , 2008, Current medical research and opinion.

[34]  M. Hudson,et al.  Antirheumatic drug use and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[35]  M. Hudson,et al.  Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. , 2005, Rheumatology.

[36]  R. Kirsner,et al.  Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. , 2005, Journal of the American Academy of Dermatology.

[37]  Cynthia S Crowson,et al.  Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases. , 2004, Rheumatic diseases clinics of North America.

[38]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[39]  J. Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[40]  C. Turesson,et al.  Extra-articular rheumatoid arthritis: prevalence and mortality. , 1999, Rheumatology.

[41]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[42]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[43]  S. R. Dahlqvist,et al.  Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. , 1997, The Journal of rheumatology.

[44]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[45]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2015 .

[46]  Cynthia S Crowson,et al.  The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases. , 2011, Rheumatology.

[47]  D. Symmons.  Mortality in rheumatoid arthritis. , 1988, British journal of rheumatology.